There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evolent Health (EVH – Research Report), Nurix Therapeutics (NRIX – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Evolent Health (EVH)
In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Evolent Health, with a price target of $51.00. The company’s shares closed last Tuesday at $30.16.
According to TipRanks.com, Tassan is a 1-star analyst with an average return of
Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $46.56, which is a 54.9% upside from current levels. In a report issued on April 5, RBC Capital also maintained a Buy rating on the stock with a $42.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nurix Therapeutics (NRIX)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. The company’s shares closed last Tuesday at $14.65.
According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of
Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $25.09, a 62.9% upside from current levels. In a report issued on April 2, Robert W. Baird also maintained a Buy rating on the stock with a $24.00 price target.
Legend Biotech (LEGN)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Legend Biotech today and set a price target of $90.00. The company’s shares closed last Tuesday at $50.12.
According to TipRanks.com, Tenthoff is a 1-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $86.58, implying a 73.2% upside from current levels. In a report issued on April 3, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EVH:
